Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19
Condition(s):Coronavirus InfectionsLast Updated:November 9, 2021Terminated
Hide Studies Not Open or Pending
Condition(s):Coronavirus InfectionsLast Updated:November 9, 2021Terminated
Condition(s):SARS-CoV-2 InfectionLast Updated:May 18, 2023Terminated
Condition(s):SARS (Severe Acute Respiratory Syndrome); COVID-19Last Updated:July 7, 2023Completed
Condition(s):COVID-19; MucormycosisLast Updated:October 28, 2021Unknown status
Condition(s):Covid19Last Updated:March 30, 2021Unknown status
Condition(s):COVID-19; Favipiravir (Favipira)Last Updated:May 26, 2020Unknown status
Condition(s):Severe Acute Respiratory Syndrome Coronavirus 2; COVID-19Last Updated:August 19, 2020Unknown status
Condition(s):COVID-19Last Updated:November 15, 2023Active, not recruiting
Condition(s):Influenza A; Influenza Type B; SARS CoV 2 Infection; RSV InfectionLast Updated:July 3, 2023Not yet recruiting
Condition(s):Covid19Last Updated:May 31, 2022Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.